Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life

The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life

Mark Vickery headshot

Top Research Reports for Mastercard, Disney & Abbott

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Disney (DIS) and Abbott (ABT).

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

Is (ABT) Outperforming Other Medical Stocks This Year?

Abbott (ABT) Gains But Lags Market: What You Should Know

Abbott (ABT) closed at $77.54 in the latest trading session, marking a +1.85% move from the prior day.

Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges

We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.

Abbott (ABT) Stock Moves -0.05%: What You Should Know

In the latest trading session, Abbott (ABT) closed at $75.67, marking a -0.05% move from the previous day.

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Abbott (ABT) closed at $75.64, marking a -0.81% move from the previous day.

Why Is Abbott (ABT) Up 3.6% Since Last Earnings Report?

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

This $4 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies

Abbott Rides on Strong CGM, Poor Rhythm Management Ails

Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.

Abbott (ABT) Upgraded to Buy: What Does It Mean for the Stock?

Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes

The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes

Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up

A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results

Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat

Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.

Mark Vickery headshot

Top Stock Reports for Verizon, Abbott & Illinois Tool Works

Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Abbott (ABT) and Illinois Tool Works (ITW).

Urmimala Biswas headshot

Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates

Henry Schein's (HSIC) strong share gains in the North American market raise optimism.

Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top

Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.

QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss

QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.

Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid

Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.

Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates

Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.

Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

Fresenius Medical (FMS) gains from solid international revenues in Q1.

HMS Holdings' (HMSY) Q1 Earnings and Revenues Beat Estimates

Top-line growth, higher commercial and state government revenues and expansion in margins aid HMS Holdings (HMSY) in Q1 earnings. However, increase in cost of services remains a woe.

Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates

Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.

AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates

Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.